01. Exhibition Overview
On October 8th, the 2024 CPHI Worldwide Pharmaceutical Exhibition kicked off in Milan. As one of the most important annual events in the global pharmaceutical industry, it attracted participants from 166 countries and regions. With over 2,400 exhibitors and 62,000 professional attendees, the exhibition covered 160,000 square meters. During the event, more than 100 conferences and forums were held, addressing various topics ranging from pharmaceutical regulations and innovative drug development to biopharmaceuticals and sustainable development.
02. JYMed’s Highlights
Shenzhen JYMed Technology Co., Ltd. (hereinafter referred to as “JYMed”), as one of the largest peptide manufacturers in China, presented new technologies, products, and collaboration opportunities to global customers at the Milan exhibition. During the event, the JYMed team engaged in in-depth discussions with pharmaceutical companies and clients from around the world, sharing insights on key issues in the peptide industry and offering valuable ideas and recommendations for the industry's future development.
JYMed boasts an international platform for the research and production of peptides, peptide-like compounds, and peptide-drug conjugates (PDCs). The company holds expertise in complex peptide synthesis, core peptide chemistry, and large-scale production technologies. It has established long-term strategic partnerships with numerous renowned global enterprises. JYMed believes that through resource sharing and complementary strengths, it can bring more hope and options to patients worldwide.
03. Exhibition Summary
Guided by the philosophy of “Peptides for a Better Future,” JYMed will continue driving pharmaceutical innovation and contributing to the health and well-being of patients around the world. We look forward to working with global peers to embrace a bright future for the pharmaceutical industry.
About JYMed
Shenzhen JYMed Technology Co., Ltd. (hereinafter referred to as JYMed) was established in 2009, specializing in the research, development, production, and sales of peptides and peptide-related products. With one research center and three major production bases, JYMed is one of the largest producers of chemically synthesized peptide APIs in China. The company's core R&D team boasts over 20 years of experience in the peptide industry and has successfully passed FDA inspections twice. JYMed’s comprehensive and efficient peptide industrialization system offers customers a full range of services, including the development and production of therapeutic peptides, veterinary peptides, antimicrobial peptides, and cosmetic peptides, as well as registration and regulatory support.
Main Business Activities
1. Domestic and international registration of peptide APIs
2. Veterinary and cosmetic peptides
3. Custom peptides and CRO, CMO, OEM services
4. PDC drugs (peptide-radionuclide, peptide-small molecule, peptide-protein, peptide-RNA)
In addition to Tirzepatide, JYMed has submitted registration filings with the FDA and CDE for several other API products, including the currently popular GLP-1RA class drugs such as Semaglutide and Liraglutide. Future customers using JYMed's products will be able to directly reference the CDE registration number or DMF file number when submitting registration applications to the FDA or CDE. This will significantly reduce the time required for preparing application documents, as well as the evaluation time and cost of product review.
Contact Us
Shenzhen JYMed Technology Co., Ltd.
Address: 8th & 9th Floors, Building 1, Shenzhen Biomedical Innovation Industrial Park, No. 14 Jinhui Road, Kengzi Subdistrict, Pingshan District, Shenzhen
Phone: +86 755-26612112
Website: http://www.jymedtech.com/
Post time: Oct-18-2024